Biotech

All Articles

Merck stops period 3 TIGIT test in lung cancer cells for futility

.Merck &amp Co.'s TIGIT system has actually suffered yet another problem. Months after shuttering a ...

After a tough year, Exscientia folds up into Recursion

.After a year specified by pipe cuts, the shift of its CEO as well as cutbacks, Exscientia will merg...

Cullinan, after $25M deal, hands back bispecific to Harbour

.Cullinan Therapeutics was actually blown away good enough with Port BioMed's bispecific immune acti...

A more detailed consider Tough Biotech's Fierce 15

.Within this full week's episode of "The Top Line," our team're diving right into Ferocious Biotech'...

Lilly experiences stage 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's gathering commemorating the approval of Alzhe...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of notable management hirings, shootings an...

Lykos are going to ask FDA to reconsider its own selection following turndown of MDMA therapy for post-traumatic stress disorder

.Adhering to a bad presenting for Lykos Therapies' MDMA applicant for trauma at a latest FDA advisor...

AN 2 fifty percents headcount, quits period 3 trial after data disappoint

.AN2 Rehabs is actually reconsidering its company in feedback to lackluster midphase data, vowing to...

Merck spends $700M for bispecific, snooping autoimmune opening and also odds to test Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 thousand beforehand to challenge Amgen in a blood stream...

Gilead pays J&ampJ $320M to go out licensing offer for seladelpar

.Along With Gilead Sciences almost an FDA selection for its own liver ailment drug seladelpar, the p...